CIDP Treatment Outcomes Correlation With First Nerve Conduction Changes: Ascertainment of Initial and Long‐Term Responders

• DOI: 10.1111/jns.70017
• Publication Date: 2025-04-07T05:39:46Z
• Authors: Thapat Wannarong; Michael P. Skolka; Natthapon Rattana...; Grace Swart; James B. Dyck; Sarah E. Berini; Divyanshu Dubey; Kamal Shouman; Marcus V. Pinto; Michelle L. Mauer...; Anthony J. Windebank; Nathan P. Staff; Christopher J. Klein
• Keywords: Nerve conduction study

ABSTRACT Background and Aims Nerve conduction studies (NCS) are integral to diagnosing chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but their role in predicting treatment outcomes remains underexplored. This study evaluates NCS changes at first follow‐up (first changes) as predictors of success CIDP, focusing on correlation with clinical over time. Methods Newly diagnosed CIDP patients meeting the 2021 EAN/PNS criteria were retrospectively evaluated. Baseline parameters compared outcomes, assessed by Neuropathy Impairment Score (NIS) Inflammatory Cause Treatment (INCAT) disability score. All received first‐line immunotherapy (intravenous immunoglobulin, corticosteroids, or plasma exchange). Results Of 39 treated patients, 26 (66.7%) responders based improving NIS trends, while 13 (33.3%) nonresponders. Responders showed significant improvements fibular compound muscle action potential (CMAP) amplitude, ulnar CMAP summated amplitudes, motor velocity. Changes amplitude consistently correlated ( R = −0.8 −0.6, p ≤ 0.004) INCAT score −0.6 −0.3, 0.032) across all intervals up 60 months. Ulnar also though associations less sustained than those amplitude. Interpretation The change is a reliable biomarker for response, amplitudes alternatives when response absent. Our findings highlight utility monitoring CIDP.